<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380651</url>
  </required_header>
  <id_info>
    <org_study_id>324/13/03/02/2014/1</org_study_id>
    <nct_id>NCT02380651</nct_id>
  </id_info>
  <brief_title>Functional Outcomes and HRQoL in Upper-extremity Sarcoma Patients After Limb Salvage</brief_title>
  <official_title>Functional Outcomes and Health Related Quality of Life in Upper-extremity Sarcoma Patients After Limb Salvage: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the functional ability and health-related quality of life (HRQoL)&#xD;
      of upper extremity sarcoma patients who have undergone limb salvage surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the functional capabilities and health-related quality&#xD;
      of life (HRQoL) of upper-extremity sarcoma patients who have undergone limb salvage surgery.&#xD;
&#xD;
      Patient hospital records are retrospectively reviewed for demographic and clinical data.&#xD;
&#xD;
      The patient recruitment takes place at the outpatient clinic of the Comprehensive Cancer&#xD;
      Center, Helsinki University Hospital, and Tampere University Hospital. The study includes a&#xD;
      cross-sectional assessment at six months follow-up with five validated questionnaires. A&#xD;
      follow-up is conducted two and five years after surgery in the outpatient clinic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life and upper-extremity functional capability</measure>
    <time_frame>6 months to five years</time_frame>
    <description>To assess health-related quality of life and upper-extremity functional capability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sarcoma recurrence</measure>
    <time_frame>6 months to five years</time_frame>
    <description>to assess sarcoma recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire-Core 30</measure>
    <time_frame>6 months to five years</time_frame>
    <description>to assess the health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the 15D health-related quality of life instrument</measure>
    <time_frame>6 months to five years</time_frame>
    <description>to assess the health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The QuickDASH</measure>
    <time_frame>6 months to five years</time_frame>
    <description>to assess the upper-extremity function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The MSTS upper extremity section</measure>
    <time_frame>6 months to five years</time_frame>
    <description>to assess the upper-extremity function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The TESS upper extremity section</measure>
    <time_frame>6 months to five years</time_frame>
    <description>to assess the upper-extremity function</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Visual Analogue Scale for pain</measure>
    <time_frame>6 months to five years</time_frame>
    <description>to assess pain</description>
  </other_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Cancer of Muscle</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Limb salvage</intervention_name>
    <description>Local or free flaps</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Upper extremity sarcoma patient who underwent limb-salvage surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Upper extremity soft tissue sarcoma locating in between scapula to arm&#xD;
&#xD;
          -  No metastasis at the time of diagnosis&#xD;
&#xD;
          -  Undergone limb salvage surgery&#xD;
&#xD;
          -  A minimum of 6 months follow-up&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18&#xD;
&#xD;
          -  No limb-salvage surgery due to sarcoma&#xD;
&#xD;
          -  Deceased&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erkki J Tukiainen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Blomqvist, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>March 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Jussi Repo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Muscle Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

